Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Consun Pharmaceutical GroupCPHGF +9.09%71 EV-to-EBITDA is 5.69 as of Aug. 06, 2026, which is 22% above its 10-year median of 4.65. GuruFocus rates CPHGF with a GF Score™ of 71/100 and a GF Value™ of $1.10 (Significantly Overvalued). The stock has 1 warning sign investors should review. Among 743 Drug Manufacturers companies, Consun Pharmaceutical Group ranks better than 81.97% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Consun Pharmaceutical Group's enterprise value is $961.9 Mil.
Consun Pharmaceutical Group's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was $169.0 Mil. Therefore, Consun Pharmaceutical Group's EV-to-EBITDA for today is 5.69.
The historical rank and industry rank for Consun Pharmaceutical Group's EV-to-EBITDA or its related term are showing as below:
CPHGF'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 0.61 Med: 4.65 Max: 13.17
Current: 5.71
During the past 13 years, the highest EV-to-EBITDA of Consun Pharmaceutical Group was 13.17. The lowest was 0.61. And the median was 4.65.
CPHGF's EV-to-EBITDA is ranked better than 81.97% of 743
companies
in the Drug Manufacturers industry
Industry Median: 13.06
vs CPHGF: 5.71
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Consun Pharmaceutical Group (OTCPK:CPHGF) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Consun Pharmaceutical Group's PE Ratio (TTM) for today is calculated as:
Consun Pharmaceutical Group's share price for today is $1.80.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Consun Pharmaceutical Group's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was $0.178.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Consun Pharmaceutical Group's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Consun Pharmaceutical Group EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Consun Pharmaceutical Group's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Consun Pharmaceutical Group's EV-to-EBITDA falls into.
Consun Pharmaceutical Group's current Enterprise Value is $961.9 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Consun Pharmaceutical Group's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was $169.0 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Consun Pharmaceutical Group (CPHGF) has a EV-to-EBITDA of 5.69 as of Aug. 06, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Consun Pharmaceutical Group. This is 22% above median its historical median of 4.65. Over the past decade, Consun Pharmaceutical Group's EV-to-EBITDA has ranged from 0.61 to 13.17. According to the industry distribution chart, Consun Pharmaceutical Group ranks #134 out of 743 companies in the Drug Manufacturers industry, placing it in the top 18%.
Is Consun Pharmaceutical Group's EV-to-EBITDA too high?
Consun Pharmaceutical Group's current EV-to-EBITDA of 5.69 is 22% above median its 10-year median of 4.65. Over the past 10 years, this metric has ranged from a low of 0.61 to a high of 13.17. The Drug Manufacturers industry median EV-to-EBITDA is 13.06. Consun Pharmaceutical Group's value of 5.69 is 56.4% below this industry median. Based on the distribution chart, Consun Pharmaceutical Group ranks #134 out of 743 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Consun Pharmaceutical Group has a GF Score™ of 71/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Consun Pharmaceutical Group's EV-to-EBITDA compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Consun Pharmaceutical Group ranks #134 out of 743 companies for EV-to-EBITDA. This places Consun Pharmaceutical Group in the top 18% of its industry — outperforming the majority of peers. The industry median EV-to-EBITDA is 13.06. Consun Pharmaceutical Group's value of 5.69 is 56.4% below this benchmark. Historically, Consun Pharmaceutical Group's own EV-to-EBITDA has ranged from 0.61 to 13.17 over the past decade. While the company's 10-year median is 4.65 vs. the industry median of 13.06, Consun Pharmaceutical Group has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 13.06, based on 743 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Consun Pharmaceutical Group's current EV-to-EBITDA of 5.69 is 56.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Consun Pharmaceutical Group. For the Drug Manufacturers industry, the median EV-to-EBITDA is 13.06 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Consun Pharmaceutical Group's current EV-to-EBITDA is 5.69, which is 22% above median its own 10-year median of 4.65. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Consun Pharmaceutical Group stock overvalued right now?
Based on GuruFocus' analysis, Consun Pharmaceutical Group (CPHGF) is currently considered Significantly Overvalued. The stock's GF Value™ is $1.10, compared to a current price of $1.80 — trading 63.6% above its estimated fair value. The current EV-to-EBITDA is 5.69, which is 22% above median its 10-year median of 4.65 and 56.4% below the Drug Manufacturers industry median of 13.06. Consun Pharmaceutical Group's overall GF Score™ is 71/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Consun Pharmaceutical Group (CPHGF), the current EV-to-EBITDA is 5.69 as of Aug. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Consun Pharmaceutical Group (CPHGF) Overvalued in 2026?
Based on GuruFocus' analysis, Consun Pharmaceutical Group stock appears to be overvalued.
The current stock price of $1.80 is trading 63.6% above its estimated GF Value™ of $1.10.
GuruFocus considers Consun Pharmaceutical Group to be Significantly Overvalued.
Key valuation signals for CPHGF:
EV-to-EBITDA: 5.69 (22% above median its 10-year median of 4.65)
GF Value™: $1.10 vs. price of $1.80 (63.6% above fair value)
Industry Position: 56.4% below the Drug Manufacturers median (#134 of 743)
No single metric tells the full story. See the CPHGF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Consun Pharmaceutical Group Ltd is a biotechnology company with a modern pharmaceutical enterprise that integrates R&D, production, and marketing. The company has two reportable segments: the Consun pharmaceutical segment, which is the key revenue driver, and makes and sells modern Chinese medicines and medical contrast medium, and the Yulin pharmaceutical segment, which manufactures and sells traditional Chinese medicines. Company derives revenue from kidney medicines, contrast mediums, orthopedics medicines, dermatologic medicines, hepatobiliary medicines, medicines for women and children, and others.
71GF Score
Get the complete analysis for CPHGF
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CPHGF has been successfully added to your 
